MALLINCKRODT ALBUNEX TEST MARKETING TO BEGIN IN EARLY SEPTEMBER
This article was originally published in The Gray Sheet
MALLINCKRODT ALBUNEX TEST MARKETING TO BEGIN IN EARLY SEPTEMBER at 10 hospitals following FDA clearance of the product Aug. 5. The approval is the agency's first for an ultrasound contrast imaging agent for use in the left side of the heart. Albunex was developed by Molecular Biosystems, Inc.; Mallinckrodt Medical has marketing rights in North and South America.
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.